

Rno	REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
1	16/LO/0422	198606	A Phase I trial of oral CCT245737	Number Agreed	5	5	Date Agreed	03/05/2019	5	03/05/2019	5	Recruitment Finished
2	16/SC/0494	211989	Triple vs dual therapy in inadequately controlled asthma	Not Available / Not Agreed			Date Agreed	14/06/2019	0	14/06/2019	0	Recruitment Finished
3	17/LO/0402	209419	IMmotion010	Number Agreed	3	3	Date Agreed	12/11/2019	3	12/11/2019	3	Recruitment Finished
4	15/NE/0350	181479	RESP 3213 (Lung Volume Reduction Coil)	Number Agreed	15	15	Date Agreed	12/11/2019	16	12/11/2019	16	Recruitment Finished
5	17/SC/0083	218035	SAXOPHONE: Safety of ApiXaban On Pediatric Heart disease On the preventioN of Embolism	Number Agreed	3	3	Date Agreed	22/03/2019	6	22/03/2019	6	Recruitment Finished
6	17/EM/0059	221778	1245.121 EMPEROR-Reduced Study CardioMEMS HF System OUS Post Approval Study	Number Agreed	7	7	Date Agreed	30/08/2019	7	30/08/2019	7	Recruitment Finished
7	17/LO/0041	219676	Approval Study	Number Agreed	10	10	Date Agreed	31/07/2019	16	31/07/2019	16	Recruitment Finished
8	17/LO/1068	224973	CO39303 A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS...	Number Agreed	4	4	Date Agreed	31/01/2019	9	31/01/2019	9	Recruitment Finished
9	17/EE/0177	220722	BOSTON: Open-label Study of SVD versus VD in patients with RRMM	Number Agreed	5	5	Date Agreed	12/11/2019	5	12/11/2019	5	Recruitment Finished
10	18/LO/1301	249407	VIVO Accuracy study	Number Agreed	6	6	Date Agreed	14/06/2019	6	14/06/2019	6	Recruitment Finished
11	18/EM/0336	251477	CEPHEUS	Number Agreed	3	3	Date Agreed	19/07/2019	3	19/07/2019	3	Recruitment Finished
12	16/EE/0196	201273	CHIL 5025 A 24 Week Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial with a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapgliflozin	Number Agreed	2	2	Date Agreed	24/09/2019	1	24/09/2019	1	Recruitment Finished
13	16/EE/0183	199109	MUSC 3998	Number Agreed	1	1	Date Agreed	12/11/2019	0	12/11/2019	0	Recruitment Finished
14	15/YH/0478	186697	HEPA - 5032 The REGENERATE Study	Number Agreed	8	8	Date Agreed	31/01/2019	0	31/01/2019	0	Withdrawn By Sponsor
15	17/NE/0092	220929	B5091007 - C.Difficile infection-9002/0359-Pfizer	Number Agreed	18	18	Date Agreed	12/11/2019	7	12/11/2019	7	Recruitment Finished
16	16/EE/0463	214371	CompLEement-1	Number Agreed	5	5	Date Agreed	30/10/2019	2	30/10/2019	2	Recruitment Finished
17	16/NW/0620	206738	Pro2tect-Correction	Number Agreed	2	2	Date Agreed	12/11/2019	0	12/11/2019	0	Recruitment Finished
18	16/NW/0621	206740	Pro2tect-Conversion	Number Agreed	2	2	Date Agreed	30/08/2019	0	30/08/2019	0	Recruitment Finished
19	17/EM/0063	213979	Gilteritinib as Maintenance After Induction/Consolidation in CR1 AML (Astellas AML Maintenance Study)	Number Agreed	2	2	Date Agreed	29/03/2019	0	29/03/2019	0	Recruitment Finished

Rno	REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
20	17/EM/0058	221776	1245.110 EMPEROR-Preserved Study (CAIN457K2340) Secukinumab compared with GP2017 in Active AS	Number Agreed	6	6	Date Agreed	12/12/2019	1	12/12/2019	1	Recruitment Finished
21	17/SW/0221	232448	Evaluation of Avelumab combined with Talazoparib in solid tumours	Number Agreed	4	4	Date Agreed	16/05/2019	1	16/05/2019	1	Recruitment Finished
22	18/LO/0416	235395	Study to evaluate the safety & efficacy of 13 weeks of SARM GSK2881078	Number Agreed	5	5	Date Agreed	07/10/2019	3	07/10/2019	3	Recruitment Finished
23	18/EE/0092	235968	C16029: Phase 2/3 Randomized, Open-Label Study in Multiple Myeloma	Number Agreed	8	8	Date Agreed	24/06/2019	7	24/06/2019	7	Recruitment Finished
24	17/NW/0546	228365	GSK3772847 in participants with Asthma with AFAD	Number Agreed	3	3	Date Agreed	11/09/2019	0	11/09/2019	0	Recruitment Finished
25	17/YH/0432	236091	MDS Clinical Utility Study OMS002-1	Number Agreed	3	3	Date Agreed	30/06/2019	2	30/06/2019	2	Recruitment Finished
26	17/LO/1672	209107	Jazz JZP963-201	Number Agreed	100	100	Date Agreed	12/11/2019	68	12/11/2019	68	Recruitment Finished
27	18/YH/0055	241341	RO5541007 in lymphoma	Number Agreed	3	3	Date Agreed	22/10/2019	1	22/10/2019	1	Recruitment Finished
28	18/SC/0037	234222	CL140FSGS	Number Agreed	3	3	Date Agreed	03/06/2019	2	03/06/2019	2	Recruitment Finished
29	18/WA/0262	245893	ANTHEM	Number Agreed	1	1	Date Agreed	18/07/2019	0	18/07/2019	0	Withdrawn By Sponsor
30	18/EM/0217	244390	Phase 2 study of the Safety and Efficacy of ADCT-402 on DLBCL Patients	Number Agreed	4	4	Date Agreed	05/11/2019	0	05/11/2019	0	Recruitment Finished
31	18/EE/0197	246434		Number Agreed	5	5	Date Agreed	28/08/2019	2	28/08/2019	2	Recruitment Finished